1245078-99-2

Downstream Products

• 1245079-64-4 4-(3-{6-[(3R,4S)-3-tert-butoxycarbonylamino-4-(2,4-difluorophenyl)pyrrolidin-1-yl]pyrimidin-5-yl}-[1,2,4]oxadiazol-5-ylmethoxy)piperidine-1-carboxylic acid isopropyl ester 
• 1351345-51-1 ((3R,4S)-4-(2,4-difluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]pyrimidin-2-yl}pyrrolidin-3-yl)carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS

Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR119. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention is directed to therapeutic compotmds of the following formula (I) which have activity as agonists of GPR 119 and are useful for the treatment of metabolic disorders including type II diabetes.